8-K: Tempest Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics announced its Q1 2025 financial results, highlighting progress with amezalpat and TPST-1495, while also revealing strategic alternatives and a workforce reduction.

Summary

• Tempest Therapeutics reported a net loss of $10.9 million, or $3.16 per share, for the quarter ended March 31, 2025, compared to a net loss of $7.9 million, or $4.62 per share, for the same period in 2024.
• Research and development expenses increased to $7.6 million from $4.3 million in the same quarter of the previous year, driven by costs related to the pivotal Phase 3 trial preparation for amezalpat in first-line HCC.
• General and administrative expenses decreased slightly to $3.3 million from $3.6 million year-over-year.
• The company ended the quarter with $21.5 million in cash and cash equivalents, down from $30.3 million at the end of 2024, with the decrease primarily due to operating activities offset by $1.5 million from an at-the-market offering program.
• Tempest is exploring strategic alternatives to advance its clinical-stage programs and maximize stockholder value.
• A reduction in force was completed on April 30, 2025.
• The company repaid $3.5 million in debt to Oxford Finance LLC in April 2025 using cash on hand.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss, decreased cash reserves, and exploration of strategic alternatives, offset by positive regulatory designations for key drug candidates.

Positives

• Amezalpat received Orphan Drug and Fast Track designations from the FDA for HCC treatment.
• TPST-1495 received Orphan Drug designation from the FDA for FAP treatment.
• The FDA issued a Study May Proceed letter for the Phase 2 trial of TPST-1495 for FAP.
• The company repaid $3.5 million in debt.
• New data presented at AACR supports the immune component of amezalpat's dual mechanism of action.

Negatives

• The company reported a net loss of $10.9 million for the quarter.
• Cash reserves decreased from $30.3 million to $21.5 million during the quarter.
• The company is exploring strategic alternatives, which may indicate financial challenges.
• A reduction in force was implemented.

Risks

• The company's ability to continue as a going concern is subject to risks and uncertainties.
• The success of strategic transactions is not guaranteed.
• Unexpected safety or efficacy data from clinical trials could negatively impact the company.
• Lower than expected clinical trial site activation or enrollment rates could delay progress.
• Changes in the regulatory environment could affect the development and approval of product candidates.
• Unexpected litigation or other disputes could arise.

Future Outlook

The company is exploring strategic alternatives to advance its clinical-stage programs and maximize stockholder value, but no specific guidance is provided.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that the amezalpat program continues to produce data that reinforce its potential as a cancer therapy.
• Stephen Brady mentioned the company is actively engaged in exploring strategic alternatives to advance its promising clinical-stage programs and maximize stockholder value.

Industry Context

The announcement highlights the ongoing challenges and strategic shifts faced by clinical-stage biotechnology companies, particularly in the oncology space, as they navigate drug development, regulatory approvals, and financial sustainability.

Comparison to Industry Standards

• Many clinical-stage biotech companies with limited revenue rely on venture capital, partnerships, or public offerings to fund operations, similar to Tempest's use of an at-the-market offering program.
• The exploration of strategic alternatives, including potential partnerships or acquisitions, is a common strategy for biotech companies facing financial constraints or seeking to accelerate drug development.
• The FDA's Orphan Drug and Fast Track designations are valuable milestones that can provide regulatory and financial benefits, such as market exclusivity and expedited review, which are sought after by companies developing treatments for rare diseases like FAP and HCC.

Stakeholder Impact

• Shareholders face uncertainty due to the exploration of strategic alternatives and financial losses.
• Employees were impacted by the reduction in force.
• Patients with HCC and FAP may benefit from the development of amezalpat and TPST-1495, respectively.
• The company's creditors are affected by the repayment of debt and the overall financial health of the company.

Next Steps

• Continue exploring strategic alternatives to advance clinical-stage programs.
• Advance the Phase 2 trial of TPST-1495 for the treatment of FAP, expected to begin in 2025.
• Prepare for the pivotal Phase 3 trial of amezalpat for the treatment of first-line HCC.

Key Dates

Keywords

Amezalpat, TPST-1495, Hepatocellular Carcinoma, Familial Adenomatous Polyposis, Orphan Drug Designation, Fast Track Designation, Phase 2 Trial, Phase 3 Trial, Financial Results, Strategic Alternatives, Reduction in Force, Cash Position, Clinical-Stage, Oncology, Tempest Therapeutics